Pixantrone

Drug Profile

Pixantrone

Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; Pixuvri

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Vermont
  • Developer Cell Therapeutics; CTI BioPharma
  • Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Alkylating agents; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Cancer
  • Discontinued Breast cancer; Myasthenia gravis

Most Recent Events

  • 02 Aug 2017 CTI BioPharma completes enrolment in the phase III PIX306 trial for Diffuse large B-cell lymphoma(Combination therapy, Second-line therapy or greater) in Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Poland, Romania, Russia, Slovakia, Spain, Ukraine, United Kingdom and USA
  • 25 Apr 2017 Pixantrone licensed to Servier in all countries world-wide excluding Israel and USA
  • 02 Mar 2017 CTI Biopharma has patent protection for pixantrone in USA, Europe Union and other countries (CTI Biopharma's form 10-K, filed in March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top